Advertisement

Antithrombotic drugs

  • F. Azougagh Oualane
  • F. Doutremepuich

Abstract

Thromboembolic diseases are major cause of global mortality. Thrombosis genesis can be induced by endothelial injury, hyperviscosity and fibrinolysis decrease. The anatomic origin of thrombosis disorders differs according to diverse types of pathophysiology.

Keywords

Platelet Aggregation Activate Partial Thromboplastin Time Anticoagulant Activity Antithrombotic Drug Medicinal Leech 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Agnelli G, Cosmi B, DI Filippo. A randomised, double blind-placebo controlled trial of dermatan sulfate for prevention of deep vein thrombosis in hip fracture. Thromb Haemost 67, 203–208, 1992.PubMedGoogle Scholar
  2. 2.
    Ashida S, Abiko Y. Inhibition of platelet aggregation by a new agent, ticlopidine. Thromb Heamost 40, 542–550, 1979.Google Scholar
  3. 3.
    Beaumont JL, Caen JP, Bernard J. Action hémorragique de l’acide acétylsalicylique au cours des maladies du sang. Bull Soc Méd Hôp Paris 71, 1087, 1985.Google Scholar
  4. 4.
    Bonne C, Martin B, Regnault F. Potentiation of antiaggregating prostaglandins by ticlopidine. Thromb Haemost 46, Abst 67, 1981.Google Scholar
  5. 5.
    Bourdon P, Jablonski JA, Chao BH, Maraganore JM. Structure—function relation-ships of hirulog peptide interactions with thrombin. FEBS Lett 294, 163–166, 1991.PubMedCrossRefGoogle Scholar
  6. 6.
    Bruno J, Yang D, Taylor LA, Leamster G. Role of platelet cAMP and prostaglandin synthesis in platelet aggregation inhibition by ticlopidine hydrochloride. Thromb Heamost 46, Abst 194, 66, 1981.Google Scholar
  7. 7.
    Cade JF, Buchanan MR, Boneu B, Okleford P. A comparison of the antithrombotic and heamorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb Res 35, 613–625, 1984.PubMedCrossRefGoogle Scholar
  8. 8.
    Chang JY. The functionnal domain of hirudin a thrombin-specific inhibitor. FEBS Lett 25, 4622–4628, 1986.Google Scholar
  9. 9.
    Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironnement of the platelet GPIIb/IIIa complex. J Clin Invest 76, 101, 1985.PubMedCrossRefGoogle Scholar
  10. 10.
    Coller BS, Folts JD, Scudder LE, Smith SR. Antithrombotic effect of a monoclonal antibody to the platelet glycoprotein IIb/lIIa receptor in an experimental animal model. Blood 68, 783–786, 1986.PubMedGoogle Scholar
  11. 11.
    Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelet produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 72, 325, 1983.PubMedCrossRefGoogle Scholar
  12. 12.
    Czapek EE, Kwaan HC, Szczecinski M. The effect of sulfated polysaccharide on ATIII. J Lab Clin Med 95, 783–790, 1980.PubMedGoogle Scholar
  13. 13.
    Ellis DJ, Roe RL, Bruno JJ, Crauston BJ, McSpadden MM. The effect of ticlopidine hydrochloride on bleeding time and platelet function in man. (ABST). Thromb Heamost 46, 1973, 1981.Google Scholar
  14. 14.
    Harker LA, Slichter SJ. Studies of platelets and fibrinogen kinetics in patients with prosthetic valves. N Engl J Med 283, 1302–1305, 1970.PubMedCrossRefGoogle Scholar
  15. 15.
    Harvey RP, Degryse E, Stefani L, Schamber F, Cazenave JP, Courtney M, Tolstoshev P, LECOCQ JP. Cloning and expression of cDNA coding for the anticoagulant hirudin from the bloodsucking leech. Proc Natl Acad Sei USA 83, 1084–1088, 1986.CrossRefGoogle Scholar
  16. 16.
    Haycraft JB. On the action of a secretion abtained from the medicinal leech on the coagulation of the blood. Proc R Soc Lond 36, 478–487, 1884.Google Scholar
  17. 17.
    Hemker HC, Frank HLL. The mechanism of action of oral anticoagulants and its consequences for the practice of oral anticoagulation. Heamostasis 15, 203–270, 1985.Google Scholar
  18. 18.
    Jakubowski JA, Maraganore JM. Inhibition of coagulation and thrombin-induced platelets activities by a synthetic dodecapeptide modeled on the carboxy-terminus of hirudin. Blood 75, 399–406, 1990.PubMedGoogle Scholar
  19. 19.
    Klöcking HP, Markwardt F. Pentosan polysulfate-induced release of plasminogen activator. Heamostasis 6, 370–374, 1977.Google Scholar
  20. 20.
    Lecompte TH, Kher A, Gaillard JL, Samama M. Pharmacologie des agents antiplaquettairesJ des Mal Vascu]aires 8, 3, 1983.Google Scholar
  21. 21.
    Lee H, Paton RC, Ruan C, Caen JP. The in vitro effect of ticlopidine on fibrinogen and factor VIII binding to human platelets. Thromb Heamost 46, 590–592, 1981.Google Scholar
  22. 22.
    Lindahl U. Biosynthesis of heparin and heparan sulfate. Upsal. J Med Sei 82, 78–79, 1977.CrossRefGoogle Scholar
  23. 23.
    Mao SJT, Yates MT, Owen TJ, Krstenansky JL. Interaction of hirudin with thrombin: Identification of a minimal binding domain that inhibits clotting activity. Biochemistry 27, 8170–8173, 1988.PubMedCrossRefGoogle Scholar
  24. 24.
    Maraganore JM, Bourdon P, Jablonski JA. Design and characterisation of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29, 7095–7101, 1990.PubMedCrossRefGoogle Scholar
  25. 25.
    Maraganore JM, Chao BH, Joseph ML, et al. Anticoagulant activity of synthetic hirudin peptides. J Biol Chem 264, 8692–8698, 1989.PubMedGoogle Scholar
  26. 26.
    Mardiguian J. Methods of preparation of low molecular weight heparins. Low Molecular Weight Heparins in Clinical Practice. Marcel Dekker Edit New-York, 7–12, 1992.Google Scholar
  27. 27.
    Markwardt F. Hirudin as an inhibitor of thrombin. Methods Enzymol 19, 924–932, 1970.CrossRefGoogle Scholar
  28. 28.
    Breckenbridge AM. Oral anticoagulant drugs. Sem Heamatol 15, 19–26, 1978.Google Scholar
  29. 29.
    Doutremepuich C, Lalanne MC, Doutremepuich F, Puyal C. Low molecular weight heparins today: Pharmacological considerations. In: Low Molecular Weight Heparins in Clinical Practice (C. Doutremepuich (Eds)). Marcel Dekker, New-York, pp 85–96 1992.Google Scholar
  30. 30.
    Johnson M, Heywood JB. Possible mode of action of ticlopidine: A novel inhibitor of platelet aggregation. Thromb Heamost 42, 367, 1979.Google Scholar
  31. 31.
    Nath N, Niewiarowski S, Joist JH. Platelet factor 4—antiheparin protein releasable from platelets: Purification and properties. J Lab Clin Med 82, 754–768, 1973.PubMedGoogle Scholar
  32. 32.
    Topol EJ, Scarpace DG, Palabrica TM, Sutor RJ, Fox IH, Maraganore JM. Hirulog, a direct thrombin inhibitor peptide, instead of heparin for routine coronary angioplasty: pilot experience. Circulation (Supplement II), 84, Abstract 2354, 1991.Google Scholar
  33. 33.
    Rajah SM, Crow MJ, Ahmad R, Watson DA. The effect of dipyridamole on platelet function. Correlation with blood levels in man. Br J Clin Pharmacol 4, 129–133, 1977.Google Scholar
  34. 34.
    Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombinheparin cofactor. J Biol Chem 248, 6490–6505, 1973.PubMedGoogle Scholar
  35. 35.
    Scully MF, Kakkar W. Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulfate (SP54). Thromb Res 36, 187–194, 1984.PubMedCrossRefGoogle Scholar
  36. 36.
    Sie P, Ofosu F, Fernandez F, Buchanau MR, Petitou M, Bonneu B. Respective role of antithrombin III and heparin cofactor II in the in vitro anticoagulant effect of heparin and of various sulphated polysaccharides. Br J Haematol 64, J 707–714, 1986.PubMedCrossRefGoogle Scholar
  37. 37.
    Soria C, Soria J, Ryckewaert JJ, Holmer E, Caen JP. Anticoagulant activities of pentosane polysulfate: comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 19, 455–463, 1980.PubMedCrossRefGoogle Scholar
  38. 38.
    Talbot MD, Ambler J, Butler KD, Findlay VS, Peters RF, Tweed MF, Wallis RB. Recombinant desulfato-hirudin (CGP39393) anticoagulant and antithrombotic properties in vivo. Thromb Haemost 61, 77–80, 1989.PubMedGoogle Scholar
  39. 39.
    Thomas DP, Marton RE, Barrowcliffe TW, Mulloy B, Johnson EA. Antifactor Xa activity of heparan sulfate., 14, 501–506, 1979.Google Scholar
  40. 40.
    Tollefsen DM, Petska CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 258, 6713, 1983.PubMedGoogle Scholar
  41. 41.
    Vairel EG. Heparins and fibrinolysis.In: Low Molecular Weight Heparins in Clinical Practice (C. Doutremepuich (Eds)). Marcel Dekker, New-York, pp 51–61, 1992.Google Scholar
  42. 42.
    Vairel EG, Brouty-Boye H, Toulemonde F, Doutremepuich C. Role de l’activité fibrinolytique indirecte des heparines et de composes voisins dans la prophylaxie des thromboses. Ann Pharma Franç 41, 339–353, 1983.Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 1994

Authors and Affiliations

  • F. Azougagh Oualane
  • F. Doutremepuich

There are no affiliations available

Personalised recommendations